BIO 2015 Dispatches: Payer Considerations, Engagement Key To Biopharma Success
This article was originally published in The Pink Sheet Daily
DVG Life Sciences' Coos de Graaf points to turf battles and differing objectives between R&D and market access divisions as another problem area for biopharma companies.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.